| 1 |
Toward a definition of intolerance of uncertainty: A review of factor analytical studies of the Intolerance of Uncertainty Scale
Jane Birrell, Kevin Meares, Andrew M. Wilkinson et al. · Clinical Psychology Review
|
2 Aug 2011 |
460 |
| 2 |
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
Johann Sebastian De Bono et al. · The Lancet Oncology
Open access |
10 Feb 2019 |
238 |
| 3 |
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Pippa G. Corrie, Andrea Marshall, Janet Dunn et al. · The Lancet Oncology
Open access |
15 Apr 2014 |
110 |
| 4 |
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
R. Charles Coombes et al. · Nature Communications
Open access |
10 Jun 2022 |
74 |
| 5 |
Enhancing research capacity across healthcare and higher education sectors: development and evaluation of an integrated model
Anne Whitworth, Shona A. Haining, Helen Stringer · BMC Health Services Research
Open access |
28 Aug 2012 |
73 |
| 6 |
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
Pippa G. Corrie et al. · Annals of Oncology
Open access120 authors |
13 Jul 2018 |
68 |
| 7 |
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii et al. · Breast Cancer Research
Open access |
31 Dec 2019 |
65 |
| 8 |
Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine, and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes
Helena Karlberg Hippard, Kalyani Govindan, Ellen M. Friedman et al. · Anesthesia & Analgesia
|
6 Jun 2012 |
43 |
| 9 |
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis
Suzy Van Sanden, Molly Murton, Anna Bobrowska et al. · Targeted Oncology
Open access |
28 Feb 2022 |
35 |
| 10 |
Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer
L. Rhoda Molife, Aurelius Gabriel Omlin, Robert J. Jones et al. · Future Oncology
|
Feb 2014 |
34 |
| 11 |
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
Bojana Milojkovic Kerklaan, S. Slater, Michael J. Flynn et al. · Investigational New Drugs
Open access |
2 Apr 2016 |
33 |
| 12 |
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
Ruth Plummer, Ayman Madi, Melinda Jeffels et al. · Cancer Chemotherapy and Pharmacology
Open access |
10 Oct 2012 |
33 |
| 13 |
Point-of-Care Cluster Randomized Trial in Stroke Secondary Prevention Using Electronic Health Records
Alex Dregan, Tjeerd Pieter van Staa, Lisa M. McDermott et al. · Stroke
Open access |
6 Jun 2014 |
33 |
| 14 |
A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Kari Lynn Kendra, Ruth Plummer, Ravi Salgia et al. · Molecular Cancer Therapeutics
Open access |
10 Dec 2014 |
31 |
| 15 |
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Enriqueta Felip et al. · Cancer Chemotherapy and Pharmacology
Open access |
17 Mar 2022 |
26 |
| 16 |
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
Jennifer R. Brown, Ruth Plummer, Todd Michael Bauer et al. · Experimental Hematology and Oncology
Open access |
3 Oct 2017 |
18 |
| 17 |
Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
Christoph Oing, Robert Glen Bristow · ESMO Open
Open access |
21 Mar 2023 |
17 |
| 18 |
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Y. Rosen, Elizabeth K. Lee et al. · JNCI Journal of the National Cancer Institute
Open access |
2 May 2024 |
16 |
| 19 |
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Rebecca Sophie Kristeleit et al. · British Journal of Cancer
Open access |
2 Aug 2020 |
13 |
| 20 |
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
Hendrik‐Tobias Arkenau, Antoîne Italiano, Gabriel Mak et al. · European Journal of Cancer
Open access |
6 Sep 2018 |
12 |
| 21 |
Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review
Ernest Kaufmann, Luca Antonelli, Peter Albers et al. · European Urology Open Science
ReviewOpen access |
7 Sep 2022 |
10 |
| 22 |
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Natalie Cook, Sarah Patricia Blagden, Juanita Suzanne Lopez et al. · Annals of Oncology
Open access |
Sep 2021 |
10 |
| 23 |
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma
Tom William Andrew, Marc Combalia, Carlos Sevilla Hernández et al. · Nature Communications
Open access |
18 Nov 2025 |
9 |
| 24 |
Social determinants of health inequalities in early phase clinical trials in Northern England
S. C. Rae, Sammy Shaya, Erik D. Taylor et al. · British Journal of Cancer
Open access |
24 Jun 2024 |
8 |
| 25 |
Understanding the experiences of cancer patients referred for a clinical trial during the COVID-19 pandemic
Ben Hood · British Journal of Nursing
Open access |
26 Jan 2023 |
4 |
| 26 |
Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany
Alastair Greystoke, M. Daumont, Caroline Rault et al. · BMC Pulmonary Medicine
Open access |
27 May 2025 |
3 |
| 27 |
382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)
Crescens Tiu, Alexandar Tzankov, Ruth Plummer et al. · Annals of Oncology
Open access |
Sep 2020 |
3 |
| 28 |
Oesophageal chest pain
Huw Alban Davies, Anna Dart, John B. Rhodes et al. · Gut
Open access |
Jul 1984 |
3 |
| 29 |
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol
Benjamin A Fisher et al. · BMJ Open
Open access |
Mar 2026 |
2 |
| 30 |
Effect of COVID-19 on cancer research nursing services
Ben Hood, Ruth E. Boyd, Tracey Crowe et al. · Cancer Nursing Practice
Open access |
22 Sep 2022 |
2 |
| 31 |
Enhancing nursing students’ awareness of the role of cancer research nurses to improve future recruitment
Ben Hood, Vivienne Wilson, Anne Croudass · Cancer Nursing Practice
Open access |
27 Sep 2021 |
2 |
| 32 |
Using patient and public involvement to improve the clinical pathway for participants in clinical trials
Ben Hood · Cancer Nursing Practice
Open access |
20 Jul 2020 |
2 |
| 33 |
The role of digital and social media within mass media anti-smoking campaigns
Andy Lloyd, James Mckendrick, Ailsa Rutter · Tobacco Induced Diseases
Open access |
15 Feb 2018 |
2 |
| 34 |
Triangulating patient and public involvement in clinical research: a cross-cohort qualitative study
Ben Hood, Andy Bojke, Catherine Cooper et al. · Research Involvement and Engagement
Open access |
3 Jun 2026 |
1 |
| 35 |
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials
Sammy Shaya, Okezie Uche–Ikonne, Bedirhan Kilerci et al. · Journal of Immunotherapy and Precision Oncology
Open access |
Aug 2025 |
1 |
| 36 |
90P Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
Pasquale Rescigno, A. H. Mahmood, M. Lagonera et al. · Annals of Oncology
Open access |
Sep 2024 |
1 |
| 37 |
80P Social determinants of health inequalities in early phase clinical trials in Northern England
S.C.A. Rae, Sammy Shaya, Erik D. Taylor et al. · ESMO Open
Open access |
Feb 2024 |
1 |
| 38 |
The effectiveness of cognitive behavioural therapy for depression in women with breast cancer: a systematic review and meta-analysis
Stephania Wieland, Sarah T. Melton, Anastasios Bastounis et al. · Behavioural and Cognitive Psychotherapy
ReviewOpen access |
23 Feb 2024 |
1 |
| 39 |
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
S. Rae, E. Ruth Plummer, L. Fitzgerald et al. · Journal of Cancer Research and Clinical Oncology
Open access |
13 Sep 2023 |
1 |
| 40 |
1704P Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH trial)
Vicky M. Coyle, Caroline Forde, Richard Adams et al. · Annals of Oncology
Open access |
Sep 2021 |
1 |
| 41 |
530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Agostina Stradella, Melissa Lynne Johnson, Sanjay Goel et al. · Annals of Oncology
Open access |
Sep 2020 |
1 |
| 42 |
600TiP A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumours (NuTide:701)
Stefan Symeonides, Francesca Aroldi, Neil M. Harris et al. · Annals of Oncology
Open access |
Sep 2020 |
1 |
| 43 |
Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
Agostina Stradella, Melissa Lynne Johnson, Sanjay Goel et al. · Annals of Oncology
Open access |
Oct 2019 |
1 |
| 44 |
Managing the side effects of vemurafenib therapy
Kim Edmonds, Julie Burton, Anna Gittins et al. · Cancer Nursing Practice
|
11 Jun 2012 |
1 |
| 45 |
Oncological emergencies
Paul HS Shaw · Cambridge University Press eBooks
Book chapter |
24 Jan 2008 |
1 |
| 46 |
Digital learning to support recruitment into cancer clinical research nursing: evaluation of a national e-learning course
Ben Hood, Holly-Ann Jardine, Ashley Reynolds et al. · Cancer Nursing Practice
|
2 Sep 2026 |
0 |
| 47 |
The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion
Christoper Hooper, Matthew Anderson, Sarah Bowen Jones et al. · Lung Cancer
Open access |
Sep 2026 |
0 |
| 48 |
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318
Hans Prenen et al. · Journal for ImmunoTherapy of Cancer
Open access |
Aug 2026 |
0 |
| 49 |
TPT 8.04 Assessing the Impact of Rehabilitation on Quality of Life Following Oesophageal Cancer Surgery: The FARO Randomised Controlled Trial
Pooja Prasad, Crystal M Aure, Jillian Macdonald et al. · British journal of surgery
Open access |
Aug 2026 |
0 |
| 50 |
SP 7.03 Patients’ Perceptions of a Rehabilitation Intervention to Restore Quality of Life Following Oesophageal Cancer Surgery: A Qualitative Study
Pooja Prasad, Joshua Brown, Claire Sedgwick et al. · British journal of surgery
|
Aug 2026 |
0 |